Friday, March 24, 2023 | Back issues
Courthouse News Service Courthouse News Service


MANHATTAN - Sanofi issued contingent value rights at inflated prices when it acquired codefendant Genzyme, and the CVRs fell by 62 percent when misleading statements about the MS drug Lemtrada were revealed, investors claim in Federal Court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.